Literature DB >> 15615534

Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3).

Mehmet Kahraman1, Sandra Sinishtaj, Patrick M Dolan, Thomas W Kensler, Sara Peleg, Uttam Saha, Samuel S Chuang, Galina Bernstein, Bozena Korczak, Gary H Posner.   

Abstract

A dozen 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3) were prepared, differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring. Although these sulfoximines were not active transcriptionally and were only very weakly antiproliferative, some of them are powerful hydroxylase enzyme inhibitors. Specifically, 24-(S)-NH phenyl sulfoximine 3a is an extremely potent CYP24 inhibitor (IC(50) = 7.4 nM) having low calcemic activity. In addition, this compound shows high selectivity toward the CYP24 enzyme in comparison to CYP27A1 (IC(50) > 1000 nM) and CYP27B (IC(50) = 554 nM).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615534     DOI: 10.1021/jm040129+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase.

Authors:  Grazia Chiellini; Simona Rapposelli; Jinge Zhu; Ilaria Massarelli; Marilena Saraceno; Anna Maria Bianucci; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Steroids       Date:  2011-11-25       Impact factor: 2.668

2.  A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.

Authors:  Jan H Beumer; Robert A Parise; Beatriz Kanterewicz; Martin Petkovich; David Z D'Argenio; Pamela A Hershberger
Journal:  Steroids       Date:  2012-01-20       Impact factor: 2.668

3.  Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone.

Authors:  David E Prosser; Martin Kaufmann; Brendan O'Leary; Valarie Byford; Glenville Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

4.  CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.

Authors:  Qiuhong Zhang; Beatriz Kanterewicz; Shama Buch; Martin Petkovich; Robert Parise; Jan Beumer; Yan Lin; Brenda Diergaarde; Pamela A Hershberger
Journal:  Mol Cell Endocrinol       Date:  2012-02-22       Impact factor: 4.102

5.  Difluoromethyl analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: Design, synthesis, and preliminary biological evaluation.

Authors:  Gary H Posner; Byung Chul Suh; Kimberly S Petersen; Patrick Dolan; Elin S Agoston; Thomas W Kensler; John T Koh; Sara Peleg
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-10       Impact factor: 4.292

Review 6.  Vitamin D metabolism and action in the prostate: implications for health and disease.

Authors:  Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

7.  The role of vitamin D in cancer prevention and treatment.

Authors:  Aruna V Krishnan; Donald L Trump; Candace S Johnson; David Feldman
Journal:  Rheum Dis Clin North Am       Date:  2012-04-12       Impact factor: 2.670

8.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

Review 9.  The role of vitamin D in cancer prevention and treatment.

Authors:  Aruna V Krishnan; Donald L Trump; Candace S Johnson; David Feldman
Journal:  Endocrinol Metab Clin North Am       Date:  2010-06       Impact factor: 4.741

10.  Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Authors:  Wei Luo; Wei-Dong Yu; Yingyu Ma; Mikhail Chernov; Donald L Trump; Candace S Johnson
Journal:  Cancer Res       Date:  2013-01-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.